ZoetisZTS

SEC filing on 2026-08-06: 8-K, 8-K filing: executive or director change.

Source: 8-K filing

Zoetis has appointed Jay Saccaro as Executive Vice President, Chief Financial Officer, and Chief Operating Officer. Starting August 17, he will lead the company's financial planning and investor relations while also managing the global manufacturing and supply network.

This move puts one leader in charge of both the company's spending and its production. It comes as Zoetis works to balance its heavy investment in new pet medicines with the need to keep operations efficient while demand for vet services is soft.

Source: Business Wire

Zoetis reported second-quarter revenue of about 2.5 billion dollars, which was flat compared to last year and slightly below what analysts expected. While adjusted earnings of $1.87 per share came in a few cents ahead of estimates, the company's organic revenue, which measures sales growth from its existing business without including the effects of currency swings or acquisitions, fell by 1 percent.

Management lowered its full-year 2026 guidance, now expecting organic revenue to decline between 1 and 3 percent. This shift is a concern for a business that usually relies on steady growth from pet treatments. It suggests that pet owners are becoming more price-sensitive and that competition is starting to eat into the sales of its older products.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

Key highlights

• Full year outlook cut: Management lowered its revenue guidance to between $9.120 billion and $9.320 billion, representing a decline of 1% to 3% on an organic basis compared to the prior year. This is a sharp reversal from its earlier forecast of 2% to 5% growth, reflecting a much harder environment for pet health spending.
• Companion animal demand falling: Sales of products for pets like dogs and cats fell 11% in the U.S. to $1.044 billion because owners are visiting clinics less often and showing more price sensitivity. This segment is usually the company's most reliable growth engine, but it is currently struggling against intense competition and a weaker economy.
• Livestock segment showing strength: The livestock division grew 23% in the U.S. to $222 million, helped by strong cattle market conditions and higher vaccine sales during poultry disease outbreaks. This performance provided a cushion for the total business while the companion animal side faced headwinds.
• Profit margins tightening: The adjusted net margin, which is the percentage of revenue kept as profit after most expenses, was 31.6% for the quarter. While this remains healthy and above the company's long term target of 25%, the full year forecast for adjusted profit growth was slashed to a range of negative 5% to negative 9%.
• Pipeline progress continues: The company is working on more than 12 potential blockbusters, which are products with at least $100 million in yearly sales, for conditions like kidney disease and anxiety. This long term innovation plan is intended to offset the impact of generic competition that is currently hurting older brands like Cerenia and Convenia.

Our take: This was a weak quarter that signals a difficult shift for the pet health leader. The 11% drop in U.S. pet product sales is the biggest concern, as it shows owners are finally pulling back on clinic visits. While the business remains profitable, the steep cut to full year guidance suggests the path back to growth will take longer than expected.